Major Depressive Disorder Clinical Trial
Official title:
CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments. The primary objective is to compare the acute (up to 12 weeks) treatment effectiveness of augmenting an antidepressant with aripiprazole or with bupropion-slow release (SR) vs. switching treatment to bupropion-SR monotherapy on symptom remission in Veterans with Major Depressive Disorder (MDD) who have not achieved optimal response after an adequate trial on antidepressant (a selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI] or mirtazapine) monotherapy. The secondary objectives are to compare the acute (up to 12 weeks) and long term (up to 36 weeks) efficacy, safety, effects on functioning, suicidality, quality of life, anxiety and other associated symptoms, costs and cost-effectiveness of each of the three treatments.
The overall aim of VAST-D is to enhance treatment outcomes for representative outpatients
diagnosed with nonpsychotic major depressive disorder (MDD) and treated in primary or
psychiatric VA care settings. In particular, VAST-D is designed to determine the comparative
effectiveness of different treatment options for participants with MDD who fail to have a
satisfactory outcome to treatment with their initial antidepressants.
These options may be conceptualized as representing two overall treatment strategies: 1)
Medication Switch - switching from the initial antidepressant to another antidepressant
medication, specifically bupropion-SR and 2) Medication Augmentation - augmenting the initial
antidepressant with a second antidepressant, specifically bupropion-SR or a second generation
antipsychotic, specifically aripiprazole. VAST-D's primary goal is to determine which of
these 3 treatment strategies is most likely to lead to remission. Other key objectives
include comparisons of response, time to remission, time to response, relapse, anxiety
symptoms, suicidal ideation and behaviors, side effects, tolerability, quality of life,
health related costs and satisfaction with participation in the study.
VAST-D will enroll 1518 total patients of both genders and all ethnic/racial and
socioeconomic backgrounds. All patients will meet Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV-TR (text revised) criteria for nonpsychotic MDD. The diagnostic criteria
for eligibility will be established by clinical interview supplemented with the 9-item
Patient Health Questionnaire (PHQ-9). Final determination for eligibility will be made by the
study clinician. Only participants with a suboptimal outcome to a well documented, adequately
delivered (dose and duration), trial with selective serotonin reuptake inhibitor (SSRI) or a
serotonin and norepinephrine reuptake inhibitor (SNRI) or mirtazapine will be eligible for
the study. Failure to achieve an adequate outcome will be ascertained by a score on the
16-item Quick Inventory of Depressive Symptomatology - Clinician rated (QIDS-C16) scale >= 16
(considered severe depression) after at least 6 weeks of treatment or QIDS-C16 >= 11
(considered moderately severe depression) after at least 8 weeks of treatment. Otherwise, the
inclusion criteria are broad and the exclusion criteria are few; participants with most
comorbid general medical or psychiatric disorders are generally included to provide a broadly
representative sample.
Participants will be randomized (1:1:1 ratio) to switch to bupropion-SR alone (n=506),
current antidepressant plus bupropion-SR (n=506), or current antidepressant plus aripiprazole
(n=506). Treatment will be guided by clinician-rated symptom measures (the PHQ-9) and global
side effects measures (the Frequency, Intensity, and Burden of Side Effects Rating or FIBSER)
obtained at each treatment visit. Acute treatment visits will occur at baseline and at weeks
1, 2, 4, 6, 8, 10, and 12 to ensure delivery of appropriate and yet vigorous and tolerable
pharmacotherapy. Participants who tolerate the acute treatment and achieve adequate response
at 12 weeks will enter the 24-week Continuation Treatment phase, during which the initial
treatment will continue and visits will occur every four weeks subsequently until patients
have been followed for 36 weeks post-randomization. The QIDS-C16 will be administered at
baseline and at each follow-up visit by an independent evaluator (who will be blinded to
treatment assignment) to measure symptoms of depression for the study outcomes of remission,
response and relapse. Neither the participant nor the treating clinician will be blinded to
treatment.
Primary hypotheses:
Primary hypothesis 1.a: Remission rate from major depressive disorder will be higher in
patients whose treatment is augmented with bupropion-SR (antidepressant + bupropion-SR)
compared to those switched to bupropion-SR monotherapy.
Primary Hypothesis 1.b: Remission rate from major depressive disorder will be higher in
patients whose treatment is augmented with aripiprazole (antidepressant + aripiprazole)
compared to those switched to bupropion-SR monotherapy.
Secondary hypotheses:
Secondary Hypothesis 2.a: Remission rate will be greater in patients whose treatment is
augmented with bupropion-SR (antidepressant + bupropion-SR) than in those augmented with
aripiprazole (antidepressant + aripiprazole).
Secondary Hypothesis 2.b: Relapse rate (within 36 weeks of the initiation of treatment) will
be lower in patients whose antidepressant is augmented with bupropion-SR (antidepressant +
bupropion-SR) than in those whose antidepressant is switched to bupropion-SR monotherapy.
Secondary Hypothesis 2.c: Relapse rate (within 36 weeks of the initiation of treatment) will
be lower in patients whose treatment is augmented with aripiprazole (antidepressant +
aripiprazole) vs. those switched to bupropion-SR monotherapy.
Secondary Hypothesis 2.d: Relapse rate (within 36 weeks of the initiation of treatment) will
be lower in patients whose treatment is augmented with bupropion-SR (antidepressant +
bupropion-SR) than in patients whose treatment was augmented with aripiprazole
(antidepressant + aripiprazole).
Secondary Hypothesis 2.e: The proportion of patients who develop akathisia, other
akathisia-like side effects (e.g., tremor, irritability, motor restlessness) and
extrapyramidal side effects will be greater in the patients whose antidepressant treatment is
augmented with aripiprazole (antidepressant + aripiprazole) compared to patients whose
treatment is augmented with bupropion-SR (antidepressant + bupropion-SR), or switched to
bupropion-SR monotherapy.
Secondary Hypothesis 2.f: The relative costs (direct and indirect) of augmenting an
antidepressant with aripiprazole (antidepressant + aripiprazole) will be greater than the
costs of antidepressant augmentation with bupropion-SR (antidepressant + bupropion-SR), and
the costs of antidepressant augmentation with bupropion-SR (antidepressant + bupropion-SR)
will be greater than the costs of switching to bupropion-SR monotherapy, and augmentation and
monotherapy with bupropion-SR will be more cost-effective than aripiprazole augmentation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |